It is worth noticing that both the U.S. Food and Drug Administration6 and the European Medical Agency7 approved adjuvant olaparib for gBRCA PV carriers with high-risk, early-stage, HER2-negative breast cancer, without considering the specifics of OlympiA criteria. The gene discussed is ERBB2; the disease is breast carcinoma.